In last trading session, Macrogenics Inc (NASDAQ:MGNX) saw 0.38 million shares changing hands with its beta currently measuring 2.01. Company’s recent per share price level of $2.22 trading at $0.02 or 0.91% at ring of the bell on the day assigns it a market valuation of $139.34M. That closing price of MGNX’s stock is at a discount of -780.18% from its 52-week high price of $19.54 and is indicating a premium of 3.15% from its 52-week low price of $2.15. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 0.49 million shares which gives us an average trading volume of 601.12K if we extend that period to 3-months.
For Macrogenics Inc (MGNX), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 2.22. Splitting up the data highlights that, out of 8 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 2 suggested the stock as a Hold whereas 6 see the stock as a Buy. 0 analyst(s) advised it as an Underweight. The company is expected to be making an EPS of -0.59 in the current quarter.
Macrogenics Inc (NASDAQ:MGNX) trade information
Upright in the green during last session for gaining 0.91%, in the last five days MGNX remained trading in the red while hitting it’s week-highest on Wednesday, 03/12/25 when the stock touched $2.22 price level, adding 10.48% to its value on the day. Macrogenics Inc’s shares saw a change of -31.69% in year-to-date performance and have moved -2.20% in past 5-day. Macrogenics Inc (NASDAQ:MGNX) showed a performance of -7.50% in past 30-days. Number of shares sold short was 5.11 million shares which calculate 7.02 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 8 to the stock, which implies a rise of 72.25% to its current value. Analysts have been projecting 4 as a low price target for the stock while placing it at a high target of 32. It follows that stock’s current price would drop -80.18% in reaching the projected high whereas dropping to the targeted low would mean a loss of -80.18% for stock’s current value.
Macrogenics Inc (MGNX) estimates and forecasts
This year revenue growth is estimated to rise 180.47% from the last financial year’s standing.
6 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of 34.17M for the same. And 4 analysts are in estimates of company making revenue of 9.32M in the next quarter. Company posted 10.72M and 9.1M of sales in current and next quarters respectively a year earlier.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 48.88% during past 5 years.
Macrogenics Inc (NASDAQ:MGNX)’s Major holders
Insiders are in possession of 2.26% of company’s total shares while institution are holding 93.80 percent of that, with stock having share float percentage of 95.97%. Investors also watch the number of corporate investors in a company very closely, which is 93.80% institutions for Macrogenics Inc that are currently holding shares of the company. BELLEVUE GROUP AG is the top institutional holder at MGNX for having 9.94 million shares of worth $42.25 million. And as of 2024-06-30, it was holding 15.8662 of the company’s outstanding shares.
The second largest institutional holder is ARMISTICE CAPITAL, LLC, which was holding about 6.0 million shares on 2024-06-30. The number of shares represents firm’s hold over 9.5749 of outstanding shares, having a total worth of $25.5 million.
On the other hand, Wasatch Ultra Growth Fund and Vanguard Total Stock Market Index Fund are the top two Mutual Funds which own company’s shares. As of Dec 31, 2024 , the former fund manager was holding 2.42 shares of worth $5.36 million or 3.85% of the total outstanding shares. The later fund manager was in possession of 1.97 shares on Dec 31, 2024 , making its stake of worth around $4.38 million in the company or a holder of 3.15% of company’s stock.
